share_log

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $95

Benzinga Real-time News ·  Feb 3, 2023 08:54

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $100 to $95.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment